Safety Interval From Increased Viscosity After COVID-19 Vaccination Among Persons With Cerebrovascular Problems.
作者信息
Mungmunpuntipantip Rujittika, Wiwanitkit Viroj
机构信息
Private Academic Consultant, Bangkok Thailand.
121766Dr DY Patil University, Pune, India.
出版信息
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039015. doi: 10.1177/10760296211039015.
Abstract
摘要
相似文献
1
Safety Interval From Increased Viscosity After COVID-19 Vaccination Among Persons With Cerebrovascular Problems.脑血管疾病患者接种新冠疫苗后因血液粘度增加的安全间隔期。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039015. doi: 10.1177/10760296211039015.
2
Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.新冠疫苗接种后的预期粘度、高粘度与既往新冠病毒感染
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211020833. doi: 10.1177/10760296211020833.
3
Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种、既往SARS-CoV-2感染的抗体反应以及改为单剂量接种。
J Med Virol. 2021 Dec;93(12):6474. doi: 10.1002/jmv.27263. Epub 2021 Aug 12.
4
[Consolidated recommendations of the Advisory Committee on Vaccines and Immunization Strategies- on prioritizing COVID-19 vaccination].[疫苗与免疫策略咨询委员会关于优先进行新冠病毒疫苗接种的综合建议]
Rev Chilena Infectol. 2021 Apr;38(2):185-188. doi: 10.4067/S0716-10182021000200185.
5
[Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination].[BNT162b2 mRNA新冠疫苗接种后血小板减少性紫癜的发生]
Rinsho Ketsueki. 2021;62(10):1519-1521. doi: 10.11406/rinketsu.62.1519.
6
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.炎症性风湿病患者接种 SARS-CoV-2 疫苗：疫苗广泛可用前的考虑因素。
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001553.
7
COVID-19 Vaccination in Pregnancy: The Benefits Outweigh the Risks.孕期接种新冠病毒疫苗：益处大于风险。
J Obstet Gynaecol Can. 2021 Jul;43(7):814-816. doi: 10.1016/j.jogc.2021.03.010.
8
Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection.美国有和没有既往 SARS-CoV-2 感染的养老院居民接种一剂 mRNA COVID-19 疫苗后的不良事件。
J Am Med Dir Assoc. 2021 Nov;22(11):2228-2232. doi: 10.1016/j.jamda.2021.08.024. Epub 2021 Aug 28.
9
Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals.不同接种间隔的新冠灭活疫苗的免疫原性。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3310-3313. doi: 10.1080/21645515.2021.1945902. Epub 2021 Aug 4.
10
Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021.疫苗接种后，熟练护理机构居民和工作人员中的 SARS-CoV-2 感染 - 伊利诺伊州芝加哥，2020 年 12 月至 2021 年 3 月。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638. doi: 10.15585/mmwr.mm7017e1.
引用本文的文献
1
COVID-19, neurovascular thrombotic problem and short summary on blood coagulation disorder: a brief review.2019冠状病毒病、神经血管血栓形成问题及凝血障碍简短综述
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):6. doi: 10.1186/s41983-021-00442-w. Epub 2022 Jan 10.
2
Venous sinus thrombosis after the second dose of SARS-CoV-2 vaccine administration.第二次接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后发生静脉窦血栓形成。
Brain Hemorrhages. 2022 Mar;3(1):41. doi: 10.1016/j.hest.2021.12.003. Epub 2021 Dec 20.
3
Change of blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome.新冠病毒疫苗接种后血液粘度的变化：对患有基础代谢综合征人群的评估
Int J Physiol Pathophysiol Pharmacol. 2021 Oct 15;13(5):148-151. eCollection 2021.
本文引用的文献
1
Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.新冠疫苗接种后的预期粘度、高粘度与既往新冠病毒感染
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211020833. doi: 10.1177/10760296211020833.
2
Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke.急性中风、短暂性脑缺血发作及中风危险因素患者的慢性血液高粘滞性
Stroke. 1991 Feb;22(2):162-8. doi: 10.1161/01.str.22.2.162.
Zotero 插件